Literature DB >> 10735918

Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion?

N D Yeomans1, J Dent.   

Abstract

This article responds to controversial issues about the long-term use of acid suppression raised in a recent article in this journal by Waldum & Brenna. Although rebound acid secretion occurs following proton pump inhibitor therapy, the clinical significance of this is unclear, but the proposal that this is a major driver of acid-related diseases is considered implausible. The polypoid deformity of the gastric corpus that can occur with long-term proton pump inhibitor therapy is not neoplastic, and therefore has no bearing on other issues raised about proton pump inhibitor therapy and gastric malignancy. Current data in humans suggest that the magnitude of serum gastrin elevation from proton pump inhibitor treatment of up to 10 years, and any theoretical risks from this, have been overstated by Waldum & Brenna. Pernicious anaemia is a model of very doubtful validity for the risks of proton pump inhibitor therapy on several grounds. The proposal that diffuse gastric carcinoma arises from acid suppression-induced stimulation of enterochromaffin-like cells is challenged vigorously, because this is based on an implausible and substantially criticized interpretation of histopathology. It is agreed that it is appropriate to be cautious about the safety of long-term acid suppression, because no data are available for lifelong treatment in humans. Such caution should be tempered by a critical assessment of the benefits of this treatment in relation to any possible risks. The substantial data that now exist from long-term treatment of humans with proton pump inhibitors has not thus far revealed any definite risks. The risk of death from anti-reflux surgery, although small, would seem to far exceed any possible risks associated with long-term proton pump inhibitor use. Available data suggest that denial of the benefits of effective acid suppressant therapy to patients with clear-cut troublesome acid related disorders is an overreaction to concerns about the biological effects of inhibiting acid secretion with proton pump inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735918     DOI: 10.1046/j.1365-2036.2000.00750.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Which PPI?

Authors:  M J Langman
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

2.  Gastro-oesophageal reflux disease in general practice. Last year's guidelines are probably biased.

Authors:  Helge L Waldum; Eiliv Brenna
Journal:  BMJ       Date:  2002-02-23

3.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

4.  Acid peptic diseases: pharmacological approach to treatment.

Authors:  Alex Mejia; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2009-05       Impact factor: 5.045

Review 5.  Importance of gastrin in the pathogenesis and treatment of gastric tumors.

Authors:  Michael D Burkitt; Andrea Varro; D Mark Pritchard
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 6.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

7.  Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Clin Transl Gastroenterol       Date:  2015-10-29       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.